Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
Phase III, international multicentre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of an intraoperative intravenous lidocaine infusion on reducing the development of persistent pain 3-months after breast cancer surgery.
PLAN is a multicentre, parallel-group, blinded, randomized controlled trial of 1,602 patients undergoing breast cancer surgery. Consented eligible patients will be randomized to receive an intravenous lidocaine: 1.5 mg/kg bolus with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room). Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution). Study medications will be prepared in blinded 50 mL syringes and labelled as per Regulatory requirements. Patients will follow up on the first 3 days after surgery, and at 3 and 12-months postoperatively to report on pain, analgesic consumption, functional, mood, and quality of life outcomes
Inclusion Criteria:
Exclusion Criteria:
James.Khan@medportal.ca416-340-4800 ext. 3243
Nour.Ayach@uhn.ca416-340-4800 ext. 4221
North York, Ontario, Canada